Quick Answer
Amylyx Pharmaceuticals, Inc. reported Net Income of -$144.74 million for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$144.74M | +52.0% |
| 2024 | -$301.74M | -712.4% |
| 2023 | $49.27M | +124.8% |
| 2022 | -$198.38M | -125.6% |
| 2021 | -$87.93M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.39M | +52.7% | +17.0% |
| June 30, 2025 | -$41.44M | +43.0% | -15.4% |
| March 31, 2025 | -$35.91M | +69.8% | +50.6% |
| September 30, 2024 | -$72.70M | -448.0% | -0.0% |
| June 30, 2024 | -$72.70M | -429.3% | +38.8% |
| March 31, 2024 | -$118.79M | -7652.0% | -668.6% |
| September 30, 2023 | $20.89M | +138.9% | -5.4% |
| June 30, 2023 | $22.07M | +140.8% | +1303.3% |
- Amylyx Pharmaceuticals, Inc. showed an increase of +52.0% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s net income has declined by 64.6% (from -$87.93 million to -$144.74 million).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: